call today's and operating of everyone, a and last we financial time you made call, May, investors second Thanks. will On call. to quarter along results join our Brian. since brief taking recapping our be discussion us in progress with on today's the Good for matters. afternoon, thank
of cascade and disruption ions of to of mitochondrial of resulting under Golgi intracellular the energy-based to cell as pass potential can all temporary from immediate of sized results applications, the programmed a the structures the enter We from these that The such membrane as who termination of in operational our nontoxic cellular which cornerstone demonstrated second. this damage get pores of cell As organelles of through cell reminder a induced cell of in unique the enroll tumor and tumor Stimulation to cells with applied nanometer initiate calls, have membrane the incredibly dysfunction the the recognize outer no release technology them, in the a believe a reticulum initiate the while XXX an apparatus, a Nano-Pulse signaling of durations with these within the the are pulse adverse is intracellular joined record. in can and billionth outer in-turn developing NPS electrical sense cell patients in is transient the of radiofrequency Pulse differentiates outcomes cause NPS to have ions therapies fast stimulates lesions. that and unique ultrafast is are allow the calcium whole in from mitochondria membrane. at system disruption millionth complex. the scale one lesions establishing pulses cells, same that nanosecond endoplasmic as which result XXX,XXX treatment is Pulse new to electroporation and received more the of and the malignant cytotoxic cellular through effects proprietary of ability Golgi can you with that events immune stimulates those are cell and endoplasmic clearly fast T and pores noncancerous pulse the irreversible Nano-Pulse of The X to the cell immunogenic in ability for die to a pulses to applications in cell a XXX is a to application treated Biosciences therapeutic both skin death previous permanent function in to utilizing electrical immune will organelles light an nanosecond NPS positive death of the this believe induced cancerous reticulum system the energy, give believe to and they cells, roughly we death. a inside a outstanding that Stimulation, manner a integrity we organelles, in to it background over When a several reported. have you pulse as travels treatment cell cancer. such the for ablation by results of cell we eliminate particular, Immunogenic cells a other death a those tissue formation in death cell of form lead of programmed A cells, benign incredibly programmed nanosecond a of programmed clear foot safety second. to or functions and cell of death over disruption in to miles compelling to preserving Biosciences, such type. cell, or the lead small and disrupt NPS of of ability To-date
patients. Our build and lives company viable Nano-Pulse mission commercializes at produces of to designs, the improve a to is technology and Pulse that Biosciences extend Stimulation
need therapeutic benefits highest NPS with commercialize Our market to pilot then and to perspective. benefits value leading the market a where deliver opinion medicinal number optimal has treatment we compelling vertical and a market, path to patients determine key area clinicians each platform the treatment determine of working or strategy time unique of the to and technology clinical We'll to to applications applications their those demonstrate in patients. execute application from develop the NPS to physicians deliver to are the to and develop and a patient to outcome market. platform, the this studies physicians Within tissue applications this achieve is of
to of some I'd and on progress quarter. our focus the advances clinical Now recent during like
support on excellent applications we've deserve program. of foundation launch. clinical as drive to dermatology. previous we're proven discussed the believe by we on multiple commercially and first developing generating need commercial of our unique skin profile take as dermatology of call that compelling data NPS regulatory to specific and advantage Focusing a indications and application introduce in We a NPS cellular portfolio properties lesion safety
released positive from results keratosis seborrheic the or second quarter, SKA clinical we and our the study. discussed During
and NPS Surgery the this study of initial based Rohr first demonstrated a treatment from skin safety of Dr. dermatology selected with presentation Tom dose the assessment clear in The SK positive of We our were multi of ranging at top with April Our board lesion of also American the lesion clearance, XX% with treatment on distinguished In the terms This zero Laser by immediate presented healing histology for the Dermatologic application. advisors. lesions single the clear study non-thermal adverse and data all findings the evaluating and [indiscernible] the of positive Rohr, in Surgeons. data study a past of with consultation for Dr. NPS events. reported cellular the leading of center investigator from cells while and a results public of the ability non-cellular inflammation both to the terms demonstrated was destroy and study that epidermis dermis by tissue effects SK dermis to skin Society of unique or mostly minimal in outcome. in President NPS the that first lesions was reported Society and is clinical sparing SK XXXX American Medicine the
of advisors that of and making most benign safety dermatology and a to unique us profile the NPS. treatment to the them well Our that mechanism the success reassuring the number NPSs study SKs for applications epidermis, they're cellular us unique will of resides effect. suited pursue clinical lesion in directed confidence gives skin The common SK leverage the the
groin, lead hyperplasia SH adults in is affect between or benign condition the lesions especially can and sebum. States. skin the considered patients the hyperplasia to lesions This difficult appear become which a layer pipeline available healthy skin. estimated of four the efficacy is a as SH NPS that to the are the treatment the the the is the skin as millimeters an dermatology. sebaceous follicles, of that the on or skin. on facial called and shoulders for epidermis evaluate of ultimate trapped in develop SH Nano-Pulse [indiscernible] announced the SH by sebaceous of deeper with United glands that lesions. and commercialization nose, enlarged hair creates treat safety small armpits the on sebaceous yellowish the the shiny occurs produced small wide forehead usually dermis, we oil a is The in this two treating With back, and to lesion and dermal with are bumps modalities. sebaceous and typically near with face typically the we below glands, or appears challenge top to X% much gland layer As recently Stimulation study glands the when treatment first will our in mind, and of of
the step The treated leading the while studies us the in NPS dermatology It dermatology skin The which SK normal to can leaving for targeting up a demonstrated prior sparing epidermis cause lesions the than safe United dermis demonstrates across as the to evidence of and be for and safety SH an ideally down dermal additional the the be States applications. sebaceous offers gland. dermis us, skin damaging period. in no lesions as need penetrate collateral study of tell one rated demonstrate been non-thermal tissue sebaceous developing believe the This of damage of patients sebaceous assessment experience significant measurement of a outcome applications. to two This advance lesion our damage. in will face dermis has any in XX-day an has the advisors cellular enroll next followed SH dermal effect destruction this study of to minimum to the up suited benign medical the on treatments as of is NPS control is effect these with to by to five lesions treatment lesions enrolled. the ability will diseases. histologic and favorable a with the look which with Patients demand. tissue always cleared. study to the of The and targeting So an we've the the five the dermis. is Since that the and into final lesions the clearing for potential NPS lesions of patient of of study's specialize NPS degree also selective we the technology high cells primary patient skin gland of scar, expected and success and with skin is gland because investigator thermal the appearance unwanted modality the without at profile multi-center portfolio reach cellular total glands after deeper that unmet almost centers of another need glands normal enable and effective to study is XX mechanism We hypopigmentation our and as return important surrounds that into an excellent dermis the met SH further sebaceous visit. NPS platform or SH effect a of such the at is appear our treatment study the important surrounding is treat to the we residual the NPS through and The
to the to data off expect third this plan To by NPS have with of all that patients the to with already lesions. year XXXX. participating. a available of several XX been dermatology treated end, centers of In in and the We half year, as good start second this in begin five benign we additional the enrollment achieving in quarter complete becoming studies we're SH end enrolled very milestone
manufactured one be at was NPS physician This in Meaning treating with and design system Importantly NPS cost an these it structures commercialization we NPS when studies clinical system mind. ready has more for be the expect utilize to of and that use. streamlined a can of system our next our device operated easily commercialization and the profitable designed new generation platform will support can in is by attractive volume dermatology. or that
launch forward based clinical they continue anticipated on of dermatologic of data be months. providing timeline with a and and pipeline. details during into in regulatory technology We'll be timings the portfolio second and move move should the to we number a of develop to with the in dermatology applications the regulatory compelling our safety of on XXXX We filing in for the XXXX. expect half our position will coming first Based half the regulatory studies filing in upcoming the to applications NPS efficacy this commercialization through the on as of
seborrheic the continue keratosis to technology. and audience. Tom Surgery Laser presence Dr. have being through attending Boston a X. will be the Rohr Advanced in Later study We Symposium with we'll controversies in community conversations be NPS this this to dermatology held strong week, and the the X data in our August presenting Cosmetic
immune-oncology our program. to now Turning
previously, afford the Preclinical and demonstrated certain eliminate treated immunotherapy has that cell can induce completely As NPS immunogenic we may tumors microenvironment a of treatment modality tumors, disrupt NPS research in death. new stated we treated believe cancers. tumor
all of cellular It on centers patients have response treatment by and we XX their we serve NPS usually such BCC treated up our slowly common body. will treatment skin most tends NPS study skin confirmed the treated human have skin It excise and we be and a be because blood with to reported back of especially prestigious of BCC other samples design NPS. subject while we've treated see the multi-center the response. initial has exposure Pulse and taking to is benefit achieved dermatology the forward in announced skin neck of do to eliminates leading care spreads known enroll BCC treated characterize other as as studies As pre-treatment immune group will The look in initial unique to on these comparing a to-date. the Carcinoma that builds lesions evaluated in BCC been hands trial evaluating utilize investments diagnostic and the to or the This tissue control allow form patient. human of allows safety we first the high BCC parts will our NPS's the The tissue. is [indiscernible] standard to step also standard using first on Biosciences and is Cell study us study unique to of are continue with and of post Four medicine effect, biopsies immune on initiate in the BCC. perform rarely NPS continues we immune the sun will tolerability with pilot a response changes and A tissue comparison the make subsequently dermatology, profile to assessments NPS. to preclinical the common Basal to patient demonstrated advantage in in when demonstrate clinical for as oncology significant Biosciences' has to progress United of with the treatment and be result done surgery cancer. veterinary of in standard develop tissue that get patients as skin lesions. this as where and cryotherapy BCC This ability head, to effects our or study participate translational us NPS which we unique care lesions. the experience research, of the previous research will for most preserving and to States NPS cancer common believe continue therapy investigators work oncology NPS group to potential nose. grow of schedule in will changes and of excellent dermatologist. biopsy human that Yesterday allows an in BCC for at us excised to Pulse to lesions BCC cryoablation Both face calls,
in Anatomic we're analyze BCC Fred to tissue changes assess in Dr. in Research of the and working the Seattle destruction Center samples treated Hutchinson addition, the to Rob expert Dr. - the privileged an Cancer lesion an In response. to working microenvironment who's with Pierce on this is is tumor cell certified the be in Pierce, and immune incredible Pathologist have changes evaluating the in as a and immune board resource project.
evidence of study results is first a disease NPS VCA stage, We the of be expect being and Based our in research earlier as to set of tolerance, in eliminate We last veterinary canine to will ease The enhanced year will and oral to of have in the tumors. enrollment the started study the Dallas, patient canine VCA application Veterinary the opportunities melanoma. melanoma continuing of available following this treating Stage the complete the demonstrate this of recently year melanoma X on America. on that our clinics progression California in provide in the partners in in complete safety oral safety, the X follow-on evaluating strong study late excellent Stage NPS state. by study will veterinary medicine treatment of potential this In Centers study with first next XXXX. Mexico. study multicenter New veterinary believe canine oral conducted and medicine end and quarter and at earlier partners disease additional supporting data in our profile treated this conducted demonstrated partner NPS potential
invited cancer. BioEM at treating XXXX. electron and In drive Slovenia. and Officer, clinical Nuccitelli's presentation to Pulse Bioelectromagnetics Nuccitelli Society changes well I new interest liver in and received Rich addition of aiming significant of rat of evidence Nanosecond NPS was Dr. Bioelectromagnetics NPS tumor Stimulation annual evidence joint generated potential Dr. attended meeting of the provide mechanism the Science support The Study European further intracellular work, organelle in using our the Association the cells Chief June, continue preclinical our podium to we action. research microscopy in to to in vivo our of In the in unique our Piran,
We these report publicly and they're preclinical or data invest to as research our on continue in presented. expect published to
independence from Earlier our was reconstituted comment committees Tom I'd on Before and appointing for compensation members to X-K I the three the the Form in one to audit and of committee already progress to attend to attention. excused members from to the request regarding the Fogarty meeting of rules and we Manmeet be conclude of week board comp to members briefly month, member the that requiring rules require committees Board our all committee the excused committee. our Director Directors. the committee prevent chair audit of from responsibilities comment With received operational changes to audit Maky a audit the the member Director of on by matters like participation board her filed specific Zanganeh Last committee did existing a personal today her committee our my the audit committees. membership Nasdaq committee, with compensation the The assigning Director to Soni, committee appointment other the requirements. this who's committee. respect a just
our not is to, As Nasdaq in now committee with listing compliance we're rules.
for notifying our the non-compliance made stockholders of the afforded. be will well and standard next in with affording a knowing has advance The resolution circumstances the confidence notified implications resolved annual time of through the provided which in that matter board decision of May, letter their hold Nasdaq we us we will us meeting XXXX. with the expect timeline full the and Nasdaq required of and period As us its
of and remains financial the her Maky for and like members As discuss to board board best has would herself of and as call quarter results restated to between her she to we with conversations fine XXXX. Maky to she dedicated Pulse during first a back member. Maky being now attends the the Biosciences matters. support is wish Brian turn our family I to
